Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain

Overview of attention for article published in Health Economics Review, May 2013

Altmetric Badge

Mentioned by

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 4,191 followers.

Es oficial (es decir, ya fue publicado): tratamiento EM con Fingolimod cuesta el doble que con acetato de Glatiramer https://t.co/GLPRQDiodh

Análisis de costes de glatiramero vs fingolimod en esclerosis múltiple. No hay q ser un lince para averiguarlo. http://t.co/ggYlURLI0v

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.